HHS an­nounces move to com­mer­cial dis­tri­b­u­tion for Mer­ck­'s an­tivi­ral Lagevrio

The US De­part­ment of Health and Hu­man Ser­vices an­nounced that Mer­ck’s Covid-19 an­tivi­ral Lagevrio will be tran­si­tioned from gov­ern­ment-man­aged dis­tri­b­u­tion to com­mer­cial dis­tri­b­u­tion this No­vem­ber.

The gov­ern­ment said it would “wind down” its dis­tri­b­u­tion be­gin­ning Oct. 2, fill­ing or­ders of the oral an­tivi­ral to a re­quest-based sys­tem. Then in ear­ly or mid-No­vem­ber, or­der­ing from the gov­ern­ment al­to­geth­er will be halt­ed. The drug has been avail­able un­der emer­gency use au­tho­riza­tion in the US since De­cem­ber 2021, but has not won full ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER